Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data

Reuters10-14

Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data

Lexicon Pharmaceuticals Inc. has presented additional clinical data and program updates from its Phase 2 pilavapadin program for diabetic peripheral neuropathic pain (DPNP) at the 19th Annual Pain Therapeutics Summit. The newly released results follow topline data from the Phase 2b PROGRESS study announced earlier in 2025, which identified the 10 mg once daily dose as the most clinically meaningful and appropriate for further development. Analyses from the Phase 2 program demonstrated a linear relationship between pilavapadin plasma levels and pain reduction, a 2-point reduction in average daily pain score at 12 weeks, and an acceptable safety and tolerability profile. Lexicon has submitted an end-of-Phase 2 meeting request to the U.S. FDA, which has been accepted, and the company is currently in discussions with potential partners. The slide presentation is available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544914-en) on October 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2575297476?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575297476","market":"fut","top_or_hot":-1,"title":"Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lexicon Pharmaceuticals Inc. has presented additional clinical data and program updates from its Phase 2 pilavapadin program for diabetic peripheral neuropathic pain (DPNP) at the 19th Annual Pain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/SMMT\">Summit</a>. The newly released results follow topline data from the Phase 2b PROGRESS study announced earlier in 2025, which identified the 10 mg once daily dose as the most clinically meaningful and appropriate for further development. Analyses from the Phase 2 program demonstrated a linear relationship between pilavapadin plasma levels and pain reduction, a 2-point reduction in average daily pain score at 12 weeks, and an acceptable safety and tolerability profile. Lexicon has submitted an end-of-Phase 2 meeting request to the U.S. FDA, which has been accepted, and the company is currently in discussions with potential partners. The slide presentation is available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544914-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lexicon Pharmaceuticals Inc. has presented additional clinical data and program updates from its Phase 2 pilavapadin program for diabetic peripheral neuropathic pain (DPNP) at the 19th Annual Pain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/SMMT\">Summit</a>. The newly released results follow topline data from the Phase 2b PROGRESS study announced earlier in 2025, which identified the 10 mg once daily dose as the most clinically meaningful and appropriate for further development. Analyses from the Phase 2 program demonstrated a linear relationship between pilavapadin plasma levels and pain reduction, a 2-point reduction in average daily pain score at 12 weeks, and an acceptable safety and tolerability profile. Lexicon has submitted an end-of-Phase 2 meeting request to the U.S. FDA, which has been accepted, and the company is currently in discussions with potential partners. The slide presentation is available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544914-en) on October 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL7dlxmq:1","article_id":"2575297476","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575297476","pubTimestamp":1760443282,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on October 14, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","BK4547":"WSB热门概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","NDAQ":"纳斯达克OMX交易所","SAVA":"Cassava Sciences Inc","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4007":"制药","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LXRX":"莱斯康制药"},"translate_title":"Lexicon Pharmaceuticals在2期数据积极后将Pilavapadin推进至治疗糖尿病周围神经病理性疼痛的3期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"LXRX":0.9,"SAVA":0.9},"content_text":"Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Trials for Diabetic Peripheral Neuropathic Pain Following Positive Phase 2 Data\n    \n\n        Lexicon Pharmaceuticals Inc. has presented additional clinical data and program updates from its Phase 2 pilavapadin program for diabetic peripheral neuropathic pain (DPNP) at the 19th Annual Pain Therapeutics Summit. The newly released results follow topline data from the Phase 2b PROGRESS study announced earlier in 2025, which identified the 10 mg once daily dose as the most clinically meaningful and appropriate for further development. Analyses from the Phase 2 program demonstrated a linear relationship between pilavapadin plasma levels and pain reduction, a 2-point reduction in average daily pain score at 12 weeks, and an acceptable safety and tolerability profile. Lexicon has submitted an end-of-Phase 2 meeting request to the U.S. FDA, which has been accepted, and the company is currently in discussions with potential partners. The slide presentation is available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544914-en) on October 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2575297476","isCrawlerRequest":true}